NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions

B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell LymphomaB-cell Lymphoma

Interventions

DRUG

IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Trial Locations (13)

RECRUITING

Westmead Hospital, Westmead

RECRUITING

Royal Hobart Hospital, Hobart

WITHDRAWN

University of Maryland Baltimore, Baltimore

RECRUITING

Royal Adelaide Hospital, Adelaide

RECRUITING

Linear Clinical Research, Perth

RECRUITING

La Fondazione e l'Istituto di Candiolo, Candiolo

RECRUITING

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan

RECRUITING

Istituto Europeo Clinico Humanitas, Milan

RECRUITING

Istituto Europeo di Oncologia, Milan

RECRUITING

Institut Catala D'Oncologia, Badalona

RECRUITING

Hospital Universitario Quironsalud Madrid, Madrid

RECRUITING

Hospital Clinico Universitario de Salamanca, Salamanca

RECRUITING

Jewish General Hospital, Montreal